HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies BELLUS Well being (BLU) Traders of Proprietary Investigation of Doable Securities Fraud, Encourages Traders and Individuals Who Could also be In a position to Help Investigation to Contact the Agency

0
44
Hagens Berman Sobol Shapiro LLP

SAN FRANCISCO, July 8, 2020 / PRNewswire / – Hagens Berman urges investors at BELLUS Health Inc. (NASDAQ: BLU) to submit their losses now. The company is investigating possible violations of federal securities laws, and certain investors may have valuable claims. Hagens Berman also encourages people who may be able to assist the firm's investigations with their lawyers.

Examination by BELLUS Health (BLU):

Hagens Berman's proprietary investigation focuses on BELLUS 'statements about the effectiveness of its lead drug candidate BLU-5937.

BLU-5937, the only BELLUS drug in clinical trials, treats Refractory Chronic Cough (RCC), a disease that affects millions of patients. Although competing treatments exist, these drugs have an associated side effect of taste loss that has hindered their use. BELLUS promoted BLU-5937 as a similarly targeted RCC, but was specifically designed to reduce the likelihood of taste loss.

But further July 6, 2020BELLUS shocked investors when it became known that BLU-5937 had missed its mark in its Phase 2 clinical trials. The company announced that BLU-5937 could not outperform the placebo when it came to reducing the frequency of cough while the patients in its phase 2 study were awake. In response, the BELLUS share price fell over 70%.

"We are focusing on investor losses and whether BELLUS has misled investors about the profitability of BLU-5937," he said Reed Kathrein, the Hagens Berman partner who led the investigation.

If you bought BELLUS shares and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Individuals with non-public information about BELLUS should review their options to help with the investigation or to use the SEC whistleblower program. Under the new program, whistleblowers who provide original information can receive rewards of up to 30 percent for every successful recovery from the SEC. Call for more information Reed Kathrein at 844-916-0895 or by email (Email protected).mailto:

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities across the country and eighty lawyers. The firm represents investors, whistleblowers, employees and consumers in complex legal disputes. More information about the company and its success can be found at hbsslaw.com. For the latest news, visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein844-916-0895

SOURCE Hagens Berman Sobol Shapiro LLP

related links

https://www.hbsslaw.com